Skip Navigation


JAC Advance Access originally published online on May 8, 2008
Journal of Antimicrobial Chemotherapy 2008 62(3):626-627; doi:10.1093/jac/dkn207
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/3/626    most recent
dkn207v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bottecchia, M.
Right arrow Articles by Soriano, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bottecchia, M.
Right arrow Articles by Soriano, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir

Marcelle Bottecchia1,2, Antonio Madejón1,2, Julie Sheldon1, Javier García-Samaniego2,3, Pablo Barreiro1 and Vincent Soriano1,*

1 Infectious Diseases Department, Hospital Carlos III, Sinesio Delgado 10, Madrid 28029, Spain 2 CIBEREHD, Madrid, Spain 3 Hepatology Unit, Hospital Carlos III, Sinesio Delgado 10, Madrid 28029, Spain

* Corresponding author. Tel: +34-91-4532650; Fax: +34-91-7336614; E-mail: vsoriano@dragonet.es

Keywords: drug resistance , hepatitis B treatment , HIV

The first 10% of the full text of this article appears below.

Sir,

Hepatitis B virus (HBV) infection is a major health problem worldwide. The World Health Organization estimates that more than 400 million people are affected. Chronic hepatitis B frequently leads to end-stage liver disease and is the leading cause of liver cancer worldwide. Current HBV therapies are inadequate to eradicate chronic infection. However, anti-HBV drugs may ameliorate liver disease progression in the short term (with normalization of transaminases, reduction in serum HBV-DNA levels and/or HBeAg seroreversion) and in the long term (with prevention of liver cirrhosis . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?